SEC Form 4 · accession 0001144204-17-031577
Checkpoint Therapeutics, Inc. · CKPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fortress Biotech, Inc.
10% Owner
Period of report
Mar 17, 2017
Accepted (ET)
Jun 7, 2017 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001651407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Mar 17, 2017 | A | 721,699 | $0.00 | A | 2,702,705 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock, $0.0001 par valueF2 | — | holding | — | — | — | — | — | Common Stock | 7,000,000 | 7,000,000 | D |
Explanation of responses
- F1The Reporting Person is entitled to an annual equity fee grant from the Issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on March 17. These shares were granted by the Issuer to the Reporting Person for the 2017 annual equity fee grant.
- F2Each share of the Issuer's Class A Common Stock is convertible at any time at the option of the Reporting Person into one share of the Issuer's Common Stock and has no expiration date.